基于混合连续与分类数据的脓毒症临床亚表型及治疗效应差异:多中心观察性研究的聚类分析
该研究基于日本两个多中心注册库(东北脓毒症注册库与FOCUSED研究),纳入16岁以上ICU脓毒症患者,使用52个入院变量,采用k-UMAP、k-prototype和KAMILA三种混合数据聚类方法,以共识聚类评估稳定性。共分析1756例患者,选出3个最稳定聚类结果(k-UMAP两个、KAMILA一个),各亚表型间住院死亡率、患者特征和治疗有效性存在差异。k-UMAP模型显示:分3类时亚表型1中重组血栓调节蛋白OR 0.37(95%CI 0.13–0.80);分5类时亚表型2中抗凝血酶III OR 0.49(95%CI 0.20–0.93);KAMILA衍生亚表型均无显著治疗效应。作者认为k-UMAP可能识别有助于揭示尚未证实有效的潜在治疗靶点的新亚表型。
要点
- 在1756例ICU脓毒症患者中,k-UMAP聚类分3类时亚表型1接受重组血栓调节蛋白的OR为0.37(95%CI 0.13–0.80),住院死亡率为结局。
- k-UMAP聚类分5类时亚表型2接受抗凝血酶III的OR为0.49(95%CI 0.20–0.93)。
- KAMILA衍生亚表型均未显示显著治疗效应。
- 各亚表型间住院死亡率、患者特征与治疗有效性存在差异,提示脓毒症治疗反应异质。
- 作者认为k-UMAP可能识别有助于揭示尚未证实有效的潜在治疗靶点的新亚表型。
适用人群与场景
- 日本ICU收治的16岁及以上脓毒症患者,来自东北脓毒症注册库与FOCUSED研究两个多中心注册库。
研究设计与关键结果
- 研究类型为多中心观察性研究的聚类分析,纳入1756例患者,使用52个入院变量,采用k-UMAP、k-prototype和KAMILA三种混合数据聚类方法,以共识聚类确定最优聚类数,结局为住院死亡率。
- 选出3个最稳定聚类结果:两个来自k-UMAP,一个来自KAMILA;各亚表型间住院死亡率、患者特征和治疗有效性存在差异。
- k-UMAP分3类时亚表型1中重组血栓调节蛋白OR 0.37(95%CI 0.13–0.80);k-UMAP分5类时亚表型2中抗凝血酶III OR 0.49(95%CI 0.20–0.93);KAMILA衍生亚表型均无显著治疗效应。
- 未进行多重比较校正,因这些为探索性分析。
证据类型、等级与局限
- 证据类型为多中心观察性研究的聚类分析(探索性分析),未进行多重比较校正。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为k-UMAP可能识别有助于揭示尚未证实有效的潜在治疗靶点的新亚表型。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is a heterogeneous syndrome; therefore, identifying subphenotypes is essential to determine the optimal treatment for each patient. Previous studies have mainly analyzed continuous variables and focused on the treatment effects in patient cohorts receiving a single intervention. In this study, we explored subphenotypes using mixed continuous and categorical data and examined multiple treatment effects for each subphenotype. METHODS: We used Fifty-two admission variables from two multicenter registries—the Tohoku Sepsis Registry and Focused Outcomes Research in Emergency Care for Acute Respiratory Distress Syndrome, Sepsis, and Trauma study—which enrolled patients aged 16 years or older with sepsis admitted to intensive care units in Japan. Cluster analysis was conducted using methods for mixed data (i.e., datasets containing both continuous and categorical variables): k-UMAP, which applies k-means clustering after dimensionality reduction via Uniform Manifold Approximation and Projection (UMAP); k-prototype; and KAMILA (KAymeans for MIxed Large data). We evaluated the stability of clustering methods and determined the optimal number of clusters using consensus clustering. Based on stable clustering results, we examined the interaction effects between treatments and subphenotypes after applying inverse probability of treatment weighting in logistic regression analysis. The outcome measure was in-hospital mortality. RESULTS: The analysis included 1,756 patients. We selected the three most stable clustering results: two from k-UMAP, and one from KAMILA. Hospital mortality, patient characteristics, and treatment effectiveness varied among these subphenotypes. Significant treatment effects were observed in the k-UMAP models: the odds ratio (OR) for recombinant thrombomodulin was 0.37 (95%CI 0.13–0.80) in subphenotype 1 when classifying three subphenotypes. The OR for antithrombin III was 0.49 (95%CI 0.20–0.93) in subphenotype 2 when classifying five subphenotypes. No KAMILA-derived subphenotype showed a significant treatment effect. No adjustment for multiple comparisons was applied because these were exploratory analyses. CONCLUSIONS: Using three clustering methods on mixed-data sepsis cohorts, we identified three to five clinically distinct subphenotypes with heterogeneous treatment responses. Our findings suggest that k-UMAP may identify novel subphenotypes that could help reveal potential treatment targets not yet proven effective.
参考来源
- Yokokawa Y, Sakurai R, Kudo D, et al. Clinical subphenotypes of sepsis based on mixed continuous and categorical data and differences in treatment effects: a cluster analysis of multicenter observational studies. Crit Care. 2026. PMID: 41540406. doi:10.1186/s13054-025-05819-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。